Positive clinical outcomes for transcatheter aortic valve implantation (TAVI) from clinical trials presented at the American Association for Thoracic Surgery and the EuroPCR 2011 annual meetings were significant for the high-risk patient, ineligible for surgery with aortic valve stenosis. Further research and product development is currently ongoing worldwide to address complications associated with TAVI. To assist with this research effort, BDC Laboratories has released several technologies aiding medical device companies with their product testing for transcatheter heart valve devices.
